Full Press Release Details
By email: melissa.kostopoulos@asx.com.au
Adviser, Listings Compliance (Melbourne) ASX Limited
Response to Price Query
We refer to your letter dated 11 July
2025 wherein the ASX notes an increase in share price of Alterity Therapeutics Limited (ASX: ATH) (Company) securities between close of
trade on 10 July 2025 to intra-day trading on 11 July 2025, in addition to a significant increase in traded volume of securities.
The Company provides the following responses
to the ASX's queries:
ASX Question 1: Is ATH aware of
any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent
trading in its securities?
No, the Company is not aware of any
information concerning it that has not been announced to the market which, if known, could explain recent trading in the Company's
ASX Question 2: If the answer to
question 1 is "yes".
Alterity Therapeutics Limited
Level 3, 460 Bourke Street, Melbourne,
T: +61 (0)3 9349 4906 | WWW.alteritytherapeutics.com
The Company's response to ASX
Question 1 is "No" and therefore ASX Question 2 is Not Applicable.
ASX Question 3: If the answer
to question 1 is "no", is there any other explanation that ATH may have for the recent trading in its securities?
The Company is not aware of any reason
or information which could be an explanation for the manner of trading in the Company's securities over the aforementioned period.
However, the Company notes that it has
previously informed the market that it is expecting to release two sets of data in mid-year 2025, namely:
In addition to market anticipation surrounding
these updates, ATH is currently scheduling investor meetings for an upcoming Non-Deal Roadshow, taking place from 31 July to 6 August
2025. During this period, Dr. Stamler will be in Australia alongside Movement Disorder Key Opinion Leader Dr. Daniel Claassen. The company
has reached out to institutional, wholesale, and high-net-worth investors, as well as analysts and brokers, to arrange one-on-one meetings
and invite them to in-person presentations.
Apart from the information outlined
above, the company is not aware of any other explanation for the recent trading activity in its shares.
ASX Question 4: Please confirm
that ATH is complying with the Listing Rules and, in particular, Listing Rule 3.1.
The Company confirms it is in compliance
with the ASX Listing Rules, in particular, ASX Listing Rule 3.1.
ASX Question 5: Please confirm
that ATH's responses to the questions above have been authorised and approved under its published continuous disclosure policy or
otherwise by its board or an officer of ATH with delegated authority from the board to respond to ASX on disclosure matters.
The Company also confirms that the above
responses have been authorised and approved under the Company's continuous disclosure policy and by its Board.
Please contact us should you have any
| /s/ Abby Macnish Niven | |
| Abby Macnish Niven | |
| Company Secretary |
For and on behalf of the Board of Alterity Therapeutics Limited
Alterity Therapeutics Limited
Suite 4, Level 14, 350 Collins Street
Melbourne Victoria 3000
By email: amacnish@alteritytherapeutics.com
Alterity Therapeutics Limited ( ATH'):
ASX refers to the following:
Request for information
In light of this, ASX asks ATH to respond separately to
each of the following questions and requests for information:
When and where to send your response
is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 9:30
AM AEST Monday, 14 July 2025. You should note that if the information requested by this letter is information required
to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ATH's obligation
is to disclose the information immediately'. This may require the information to be disclosed before the deadline set out
in the previous paragraph and may require ATH to request a trading halt immediately.
Your response should be sent to me
by e-mail at ListingsComplianceMelbourne@asx.com.au. It should not be sent directly to the ASX Market Announcements Office.
This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published
on the ASX Market Announcements Platform.
If you are unable to respond to this
letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately,
you should discuss with us whether it is appropriate to request a trading halt in ATH's securities under Listing Rule 17.1. If you
wish a trading halt, you must tell us:
We require the request for a trading
halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which
it is granted. You can find further information about trading halts in Guidance Note 16 Trading Halts & Voluntary Suspensions.
If you are unable to respond to this letter by the time
specified above, ASX will likely suspend trading in ATH's securities under Listing Rule 17.3.
Listing Rules 3.1 and 3.1A
In responding to this letter, you should
have regard to ATH's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 Continuous Disclosure: Listing
Rules 3.1 - 3.1B. It should be noted that ATH's obligation to disclose information under Listing Rule 3.1 is not confined
to, nor is it necessarily satisfied by, answering the questions set out in this letter.
Release of correspondence between ASX and entity
ASX reserves the right to release
all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.
| Regards | |
| ASX Compliance |
ASX Customer Service Centre 131 279 | asx.com.au